Metabonomic Profiling of Bladder
Cancer
- Publication date
- Publisher
Abstract
Early diagnosis and life-long surveillance
are clinically important
to improve the long-term survival of bladder cancer patients. Currently,
a noninvasive biomarker that is as sensitive and specific as cystoscopy
in detecting bladder tumors is lacking. Metabonomics is a complementary
approach for identifying perturbed metabolic pathways in bladder cancer.
Significant progress has been made using modern metabonomic techniques
to characterize and distinguish bladder cancer patients from control
subjects, identify marker metabolites, and shed insights on the disease
biology and potential therapeutic targets. With its rapid development,
metabonomics has the potential to impact the clinical management of
bladder cancer patients in the future by revolutionizing the diagnosis
and life-long surveillance strategies and stratifying patients for
diagnostic, surgical, and therapeutic clinical trials. An introduction
to metabonomics, typical metabonomic workflow, and critical evaluation
of metabonomic investigations in identifying biomarkers for the diagnosis
of bladder cancer are presented